Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Økonomisk Ugebrev Life Science Investor Conference August 2025
17 slides from Expres2ion Biotech Holding Ab's conference presentation, Aug 27, 2025
Slide 1: Life Science Investor, 27 August 2025
BIOTECH i? ————— pe expreScion — Ce] ‘iy Life Science Investor 27 August 2025 Innovative " vaccines for a healthier : world Bent Frandsen — CEO ™ iP konferencer STO: EXPRS2 & Seminarer ExpreSZion Biotech Holdin AB Fi (1g. Nr. 59035-3729 “" r
Slide 2: We Are a Platform-Based Vaccine Company
expreSeion BIOTECH We Are a Platform-Based Vaccine Company Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform Target Pre-clinical DISEASE Project/Target ID Identification Pharmacology _ cGMP / Tox Phase | Phase Il Phase ill Collaboration Partner Platform ES
Slide 3: We Are Publicly Traded on NASDAQ First North
expreSeion We Are Publicly Traded on NASDAQ First North “ 9,000+ shareholders, primarily in Denmark and Sweden, support liquidity in 2.658,346 shares (~2.7 million) ExpreS2ion Biotech Holding AB “al ExpreS2ion Biotech Holding AB * Listed on Nasdaq Biotechnologies ApS First North Growth Market since
Slide 4: Extensive Vaccine Development and Oncology Experience
Extensive Vaccine Development and Oncology Experience Fully capable of executing to phase Il POC Leadership team Bent U. Frandsen CEO MSc, Copenhagen Business School Dr. Max Segaard cso PhD, University College London Keith Alexander CFO. MBA, The Wharton School 30 years life science management, busi
Slide 5: The Most Common Cancer
expreSceion BIOTECH The Most Common Cancer 8 women will be diagnosed with invasive breast cancer (BC) in her lifetime of BC tumors, HER2 is overexpressed, leading to more aggressive disease and increased mortality! deaths worldwide in 2022 due to breast cancer? develop resistance against current sta
Slide 6: Standard of Care in HER2-Positive Breast Cancer
Standard of Care in HER2-Positive expreSzion Breast Cancer Addressing SoC limitations including resistance, toxicity, and cost with a novel immunotherapeutic approach 34 line or higher Room for improvement of SoC Side effects Resistance to therapy Non-targeted e : Repeated dosing required therapies
Slide 7: Beyond Monoclonals: ES2B-C001 Targets Multiple HER2 Epitopes
expreSeion BIOTECH Beyond Monoclonals: ESB2-C001 Targets Multiple HER2 Epitopes Our proprietary solution f Unique selling point co a OI HER2 receptors The first vaccine to target the entire ; extracellular domain of the HER2- send signals telling | ; cells to grow and | receptor in a VLP construct |
Slide 8: Phase I (First-in-Human) Underway — First Patients Dosed
Phase | (First-in-Human) Underway — First gugseXP 1253/22 Patients Dosed Open-label, dose escalation Phase | in metastatic HER2+ and HER2-low breast cancer Medical University of Vienna activated; adding 2 new Austrian sites Up to 27 planned; includes escalation and expansion cohorts Escalating doses
Slide 9: Potential Development Path
expreScion Potential Development Path (Subject to lon Phase | Results) Phase II could begin in 2027; accelerated timeline under evaluation 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Phase! in Patients iq with Breast Cancer Phase II in Patients wit 4 Breast Cancer E Concurrent Phase
Slide 10: Significant Market Opportunity
Significant Market Opportunity ES2B-CO001 is a First-in-Class breast cancer immunotherapy, targeting the entire extracellular domain of HER2 Patient distribution by region and cancer type! 1,000,000 800,000 Expansion to additional iz patient groups 600,000 400,000 — P| = 200,000 . x = HER2+ BC HER2-
Slide 11: University of Oxford Malaria Vaccine Candidates
University of Oxford Malaria Vaccine Candidates New trials, updated timelines and recruitment progress expreSeion BIOTECH Vaccines in trial Trial abbreviation Phase Sites Trial status Estimated completion : ; VAC-085 | Oxford, UK Concluded vy March 2025 Pfs48/45 in Matrix-M VAC-099 Ib INSTech, Burki
Slide 12: Other Programs Largely Grant-Sponsored and Consortium Driven
Other Programs Largely Grant-Sponsored expreszion and Consortium Driven Research initiatives progressed to early preclinical maturity Nipah/Hendra vaccine with the VICI- Disease Consortium + 100% grant funded to Phase I/Ila completion + Lead antigen selection in progress + Progress in analytical met
Slide 13: Upcoming Catalysts
expreScion BIOTECH Upcoming Catalysts Expected Data Readouts & Deals on the Horizon NS Clinical & Pipeline Data + ES2B-CO01: Safety/tolerability readout + ES2B-CO01: Immunogenicity & early efficacy signals (if observable at this early stage) + Oxford malaria trials data readouts — Clinical results f
Slide 14: Net sales and other operating income
Net sales Other operating income 1Q23 3Q23 1Q24 3Q24 1Q25 1Q23 3Q23 1Q24 3Q24 1Q25
Slide 15: Expense Discipline: External R&D spend lower, cost base streamlined
Expense Discipline: External R&D spend lower, = °*P'e5si24 cost base streamlined SEK ‘000s Operating expense R&D costs (external) ie} fo} a P| -5,000 | | | | I -10,000 ———— 10% YoY -10,000 -15,000 ly -20,000 Volatile & dependent upon pipeline activities 1Q23 2Q23 3Q23 4Q23 1024 2Q24 3Q24 4Q24 1925 2
Slide 16: Q&A
expreSceion BIOTECH Q&A Innovative vaccines for a _ investor@ expres2ionbio.com https://investor. expres2ionbio.com
Slide 17: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentati
ExpreS2ion Biotech Holding — Økonomisk Ugebrev Life Science Investor Conference August 2025 on 6ix